Your browser doesn't support javascript.
loading
Assessment of fibrosis and vascularization of bone marrow stroma of chronic myeloid Leukemia patients treated with imatinib mesylate and their relationship with the cytogenetic response / Avaliação da fibrose e vascularização do estroma da medula óssea de pacientes com leucemia mielóide crônica tratados com mesilato de imatinibe e sua relação com a resposta citogenética
Jesus, Caroline Regina de; I-Ching, Lee; Neiva, Teresinha de Jesus Carvalho; Vituri, Cidônia de Lourdes.
  • Jesus, Caroline Regina de; Oncology Research Center. Laboratory of Pathology. Florianópolis. BR
  • I-Ching, Lee; Oncology Research Center. Laboratory of Pathology. Florianópolis. BR
  • Neiva, Teresinha de Jesus Carvalho; Universidade Federal de Santa Catarina. Center for Health Sciences. Department of Clinical Analyses.
  • Vituri, Cidônia de Lourdes; Universidade Federal de Santa Catarina. Center for Health Sciences. Department of Clinical Analyses.
Braz. j. pharm. sci ; 47(2): 313-322, Apr.-June 2011. ilus, tab
Article in English | LILACS | ID: lil-595819
ABSTRACT
Chronic Myeloid Leukemia (CML) is a myeloproliferative disease characterized by the presence of the Philadelphia chromosome (translocation between chromosomes 9 and 22), resulting in the formation of the hybrid BCR-ABL protein. Currently, the treatment of CML patients is performed with imatinib mesylate (IM), which promotes the elimination of leukemic cells by inhibiting the kinase activity of BCR-ABL. This study evaluated the effectiveness of IM by monitoring 22 CML patients in a chronic phase treated at the CEPON/SC with IM for a minimum follow-up period of two years. Cytogenetic Response (CR) and bone marrow biopsies (BMB) were evaluated before and after IM treatment. BMB were evaluated by detection of reticulin degree and vascularization. The results were correlated to the CR. Mean time to achieve CR was 9 months and was attained by 77.27 percent of the patients. The results from the initial BMB analysis showed that 59.09 percent presented reticulin of between 2+ and 4+ whereas after treatment, only 27.17 percent presented this degree. With regard to vascularization of the initial sample, 90.91 percent were graded between II and IV, whereas after treatment, 40.91 percent had this degree. The results suggest a positive correlation of degree of reticulin and vascularization with CR.
RESUMO
A Leucemia Mielóide Crônica (LMC) é uma doença mieloproliferativa caracterizada pela presença do cromossomo Filadélfia (translocação entre os cromossomos 9 e 22), que resulta na formação da proteína híbrida BCR-ABL. Atualmente o tratamento de pacientes com LMC é realizado com mesilato de imatinibe (MI), o qual promove a eliminação das células leucêmicas pela inibição da atividade quinase de BCR-ABL. O presente estudo avaliou a eficácia do MI por meio do acompanhamento de pacientes portadores de LMC em fase crônica, atendidos no CEPON/SC tratados com MI pelo tempo mínimo de dois anos. Foram avaliadas a Resposta Citogenética (RC) e as biópsias de medula óssea (BMO) antes e após o tratamento com MI. As BMO foram avaliadas quanto ao grau de reticulina e vascularização. Os resultados correlacionaram-se com a RC cujo tempo médio para obtenção da RC foi de 9 meses, sendo atingida por 77.27 por cento dos pacientes. Na primeira BMO, 59.09 por cento dos pacientes apresentaram grau de reticulina entre 2+ e 4+ e após o tratamento, apenas 27.17 por cento apresentaram esta graduação. Quanto à vascularização da primeira amostra, 90.91 por cento foram graduadas entre II e IV e após o tratamento, 40.91 por cento apresentaram esta graduação. Os resultados sugerem uma correlação diretamente proporcional entre os graus de reticulina e vascularização com a RC.
Subject(s)


Full text: Available Index: LILACS (Americas) Main subject: Fibrosis / Leukemia, Myelogenous, Chronic, BCR-ABL Positive / Mesylates / Cytogenetics Type of study: Evaluation studies Limits: Humans Country/Region as subject: South America / Brazil Language: English Journal: Braz. j. pharm. sci Year: 2011 Type: Article Affiliation country: Brazil Institution/Affiliation country: Oncology Research Center/BR

Similar

MEDLINE

...
LILACS

LIS


Full text: Available Index: LILACS (Americas) Main subject: Fibrosis / Leukemia, Myelogenous, Chronic, BCR-ABL Positive / Mesylates / Cytogenetics Type of study: Evaluation studies Limits: Humans Country/Region as subject: South America / Brazil Language: English Journal: Braz. j. pharm. sci Year: 2011 Type: Article Affiliation country: Brazil Institution/Affiliation country: Oncology Research Center/BR